Y. ZHAO* ET AL. (TAKEDA CALIFORNIA, SAN DIEGO, MILLENIUM PHARMACEUTICALS INC., CAMBRIDGE AND IRIX PHARMACEUTICALS, GREENVILLE, USA)

Process Research and Kilogram Synthesis of an Investigational, Potent MEK Inhibitor Org. Process Res. Dev. 2012, 16, 1652–1659.

Synthesis of TAK-733

Significance: MEK kinases regulate the pathway that mediates proliferative and anti-apoptotic signaling factors that promote tumor growth and metastasis. TAK-733 is an MEK kinase inhibitor that entered phase I clinical trials for the treatment of cancer. A noteworthy feature of this short synthesis (25% yield overall) is the one-pot, three-step synthesis of the fluoropyridone **D**, in which the fluorine atom is present at the outset.

Comment: The reaction of **F** with the nosylate **G** gave a mixture of N- and O-alkylation products (8:1) from which the desired N-alkylation product was isolated by crystallization. The mixture of N-methyl pyrrolidine (NMP) and methanol used in the final deprotection step, helped to ensure formation of the desired polymorph. The nine-step discovery synthesis (3% overall yield) is also presented.

SYNFACTS Contributors: Philip Kocienski Synfacts 2013, 9(1), 0009 Published online: 17.12.2012 **DOI:** 10.1055/s-0032-1317725; **Reg-No.:** K09812SF Synthesis of Natural Products and Potential Drugs

Key words

TAK-733
MEK inhibitors
3-fluoropyridone
cascade reaction